Crystagen is a bioregulator peptide targeting thymic tissue — the primary lymphoid organ responsible for T-cell maturation, immune education, and the lifelong programming of adaptive immunity. Part of the Khavinson series of tissue-specific short peptides, Crystagen activates gene expression in thymic stromal cells and thymocyte precursors that has been progressively silenced by the thymic involution that begins in early adulthood and accelerates to near-complete atrophy by age 50–60.

Thymic involution is one of the most consequential aging processes in the body, and one of the best characterized at the molecular level. The thymus involutes — shrinks and is replaced by fat tissue — beginning in puberty and accelerating in the third and fourth decades. By age 50, the thymus has lost roughly 80% of its functional parenchyma; by 70, little functional thymic tissue remains. This progressive loss directly translates to reduced naive T-cell output, shrinking T-cell receptor diversity, and progressively compromised adaptive immune capacity. The cumulative consequence is the immune aging (immunosenescence) that makes elderly individuals disproportionately vulnerable to infections, cancers, and autoimmune dysregulation.

Crystagen's peptide sequence was derived from thymic tissue and activates the specific gene expression programs of thymic stromal cells (thymic epithelial cells, dendritic cells, macrophages) responsible for T-cell education and maturation. The epigenetic mechanism — histone-DNA binding and chromatin remodeling to reactivate silenced promoters — restores expression of thymic hormones (thymosin-α1, thymulin, thymopoietin), MHC molecules necessary for T-cell selection, cytokines directing T-cell lineage commitment, and adhesion molecules maintaining the thymic microenvironment architecture that T-cell maturation requires.

Khavinson group research demonstrates Crystagen's effects on thymic function restoration. In aging animals, Crystagen treatment increased thymic weight (reversal of involution), increased thymocyte cellularity, improved T-cell receptor diversity measures, and enhanced T-cell proliferative response to mitogenic stimulation. Immunological outcomes included better antibody response to novel antigens, improved pathogen clearance, and reduced inflammatory cytokine dysregulation — the chronic low-grade inflammation ("inflammaging") that characterizes immune aging and drives multiple age-related diseases.

Human clinical applications in the Khavinson group's work include aging populations with documented immune decline, frequent infection patterns, cancer patients with immune suppression from treatment, and prevention-oriented protocols in middle-aged individuals. Published outcomes include improved lymphocyte counts and subpopulation balance, better response to vaccination (particularly relevant in elderly populations where vaccine efficacy drops precipitously), and reduced infection frequency over follow-up periods. Crystagen is distinct from Thymosin Alpha-1 (a single thymic hormone that functions as a direct immunostimulant) — Crystagen's epigenetic mechanism restores the entire thymic microenvironment gene expression program rather than supplementing a single thymic hormone.

Protocol: 2mg/day for 10 consecutive days, repeated 2–4 times per year. Crystagen combines synergistically with Thymosin Alpha-1 (direct thymic hormone supplementation) and Vilon (thymus-derived dipeptide with complementary T-cell activation properties) for comprehensive thymic immune restoration.